Neuroone Medical Technologies is trading at $1.01, up 10.82%, after announcing its first pharmaceutical-industry purchase order for its StereoCED drug-delivery platform.
- Announced October 22, 2026, the order supports a preclinical animal research program for a Tier 1 global pharmaceutical company, expected to begin early next year.
- The announcement marks a commercial milestone; StereoCED is not FDA-cleared or approved.
- Broader healthcare strength offers additional context, while the wider market is lower.